Congestion is the driving force behind heart failure

Current Heart Failure Reports

Volumn 9, Issue 3, 2012, Pages 219-227

  Guglin, Maya ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Congestion; Diuretics; Ejection fraction; Heart failure

Indexed keywords

AMILORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; IBOPAMINE; IRBESARTAN; LISINOPRIL; PLACEBO; SILDENAFIL; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIORENAL SYNDROME; CREATININE CLEARANCE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG VASOCONSTRICTION; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS CONGESTION; VENTRICULAR ASSIST DEVICE; BLOOD; DRUG EFFECT; FORWARD HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING;

CARDIAC OUTPUT, LOW; CARDIO-RENAL SYNDROME; DIURETICS; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; NATRIURETIC PEPTIDE, BRAIN; STROKE VOLUME; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 84871880314     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0093-9     Document Type: Article

References (74)

1. Yancy CW, Fonarow GC, Committee ASA. Quality of care and outcomes in acute decompensated heart failure: the ADHERE registry. Curr Heart Fail Rep. 2004;1:121-8.
2. Tallaj JAP, AaronM, AbrahamW, Heywood JBR, Cho Y, Bennett T. Relationship between right ventricular pressures and heart failure events in patients with heart failure. J Card Fail. 2007;13:S178-9.
3. Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433-41.
4. Stevenson LW, Zile M, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010;3:580-7. This paper demonstrates the importance of congestion and its management for hospital admissions.
5. Adamson PB, Magalski A, Braunschweig F, Bohm M, Reynolds D, Steinhaus D, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565-71. (Pubitemid 36223320)
6. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658-66. This article on the results of the CHAMPION trial demonstrates reduction in heart failure admission rates with hemodynamic monitoring.
7. Sharma GV, Woods PA, Lindsey N, O'Connell C, Connolly L, Joseph J, et al. Noninvasive monitoring of left ventricular enddiastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial. J Card Fail. 2011;17:718-25. This paper further develops the idea of benefits of guiding the therapy in heart failure by hemodynamic parameters.
8. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49:1733-9. (Pubitemid 46589928)
9. Januzzi Jr. JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881-9. This article is interesting in several respects: it shows the importance of BNP-guided strategy, and highlights the interactions between systolic function and congestion.
10. Lee DAP, Stukel T, Alter D, Chong A, PArker J, Tu J. " Dosedependent" impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med. 2009;122:162.e1-.e9.
11. Guglin M. Key role of congestion in natural history of heart failure. Int J Gen Med. 2011;4:585-91. This paper underscores the inconsistencies in current understanding of the concept of heart failure, and suggests a new model explaining all varieties of the disease.
12. Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Hear Fail. 2010;12:974-82.
13. Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146-50. (Pubitemid 46578202)
14. Kjaergaard J, Akkan D, Iversen KK, Kober L, Torp-Pedersen C, Hassager C. Right ventricular dysfunction as an independent predictor of short- And long-term mortality in patients with heart failure. Eur J Heart Fail. 2007;9:610-6. (Pubitemid 46702826)
15. Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, et al. Pulmonary pressures and death in heart failure a community study. J Am Coll Cardiol. 2012;59:222-31. This study from Mayo Clinic shows the importance of pulmonary hypertension as a prognostic factor in heart failure.
16. Neuman Y, Kotliroff A, Bental T, Siegel RJ, David D, Lishner M. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol. 2007.
17. Dini FL, Nuti R, Barsotti L, Baldini U, Dell'Anna R, Micheli G. Doppler-derived mitral and pulmonary venous flow variables are predictors of pulmonary hypertension in dilated cardiomyopathy. Echocardiography. 2002;19:457-65. (Pubitemid 35026178)
18. Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol. 1997;29:153-9. (Pubitemid 27028733)
19. GuglinM. Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence. Curr Heart Fail Rep. 2011;8:219-25.
20. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-74. This study demonstrated hemodynamic and clinical benefits of sildenafil in heart failure with preserved systolic function.
21. Heywood JT, Fonarow GC, Costanzo MR,Mathur VS,Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422-30. (Pubitemid 47179911)
22. Maeder MHD, Kaye D. Does tricuspid regurgitation contribute to renal dysfunction in patients with heart failure. J Card Fail. 2008;14:S84.
23. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-96.
24. Guglin M, Rivero A, Matar F, Garcia M. Renal dysfunction in heart failure is due to congestion but not low output. Clin Cardiol. 2011;34:113-6.
25. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-9. (Pubitemid 44079340)
26. AnsariM, AlexanderM, Tutar A, MassieBM. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. Am Heart J. 2003;146:115-20. (Pubitemid 36851309)
27. Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart. 2005;91:907-13. (Pubitemid 40874079)
28. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA: J Am Med Assoc. 2006;296:2209-16. (Pubitemid 44708051)
29. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50:768-77. (Pubitemid 47243795)
30. Varela-Roman A, Gonzalez-Juanatey JR, Basante P, Trillo R, Garcia- Seara J, Martinez-Sande JL, et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart. 2002;88:249-54. (Pubitemid 34913506)
31. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-9. (Pubitemid 44088349)
32. Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pena MG, Gonzalez-Juanatey Jr. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart (British Cardiac Society). 2005;91:489-94. (Pubitemid 40432779)
33. Senni M, RedfieldMM. Heart failure with preserved systolic function. A different natural history̌ J Am Coll Cardiol. 2001;38:1277-82. (Pubitemid 33032998)
34. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-55.
35. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or 055%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol. 2008;101:1151-6.
36. Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-Analysis. Eur Heart J. 2011. doi:10.1093/eurheartj/ehr254
37. Grigorian-Shamagian L, Otero Ravina F, Abu Assi E, Vidal Perez R, Teijeira-Fernandez E, Varela Roman A, et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. Am Hear J. 2008;156:1184-90.
38. Al-Khatib SM, Shaw LK, O'Connor C, Kong M, Califf RM. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231-5. (Pubitemid 350115779)
39. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMpreserved trial. Lancet. 2003;362:777-81. (Pubitemid 37093918)
40. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-45. (Pubitemid 44453578)
41. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-67.
42. Andrew P. Diastolic heart failure demystified. Chest. 2003;124:744-53. (Pubitemid 37000159)
43. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologicmechanisms. J Card Fail. 2005;11:177-87. (Pubitemid 40462419)
44. Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the cardiovascular health study. J Am Coll Cardiol. 2007;49:972-81.
45. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-90. (Pubitemid 46625948)
46. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503-8. (Pubitemid 34263285)
47. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- And gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112:2254-62. (Pubitemid 41464567)
48. Victor BM, Barron JT. Diastolic heart failure versus diastolic dysfunction: difference in renal function. Clin Cardiol. 2010;33:770-4.
49. Bowling CB, Feller MA, Mujib M, Pawar PP, Zhang Y, Ekundayo OJ, et al. Relationship between stage of kidney disease and incident heart failure in older adults. Am J Nephrol. 2011;34:135-41.
50. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1:91-7.
51. Zafrir B, Paz H, Wolff R, Salman N, Merhavi D, Lewis BS, et al. Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. Eur J Intern Med. 2011;22:53-6.
52. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (I-preserve) trial. Circulation. 2010;121:1393-405.
53. Grigorian Shamagian L, Gonzalez-Juanatey JR, Roman AV, Acuna JM, Lamela AV. The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. Eur Heart J. 2005;26:2251-8. (Pubitemid 41541388)
54. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76-84. (Pubitemid 43005168)
55. Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole- Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987;2:709-11. (Pubitemid 17125694)
56. Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton Jr. Symptomatic assessment of patients with heart failure: doubleblind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet. 1986;2:770-2. (Pubitemid 16007029)
57. van Kraaij DJ, Jansen RW, Bruijns E, Gribnau FW, Hoefnagels WH. Diuretic usage and withdrawal patterns in a Dutch geriatric patient population. J Am Geriatr Soc. 1997;45:918-22. (Pubitemid 27330119)
58. Mathur PN, Pugsley SO, Powles AC, McEwan MP, Campbell EJ. Effect of diuretics on cardiopulmonary performance in severe chronic airflow obstruction. A controlled clinical trial. Arch Intern Med. 1984;144:2154-7. (Pubitemid 15215502)
59. Andrews R, Charlesworth A, Evans A, Cowley AJ. A doubleblind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. Eur Heart J. 1997;18:852-7. (Pubitemid 27208158)
60. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:881-6. (Pubitemid 24158309)
61. Ahmed A, Young JB, Love TE, Levesque R, Pitt B. A propensitymatched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol. 2008;125:246-53. (Pubitemid 351400220)
62. Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31-8. (Pubitemid 34734752)
63. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-64. (Pubitemid 43817867)
64. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-8. (Pubitemid 37000189)
65. Guglin M. Reappraisal of the role of diuretics in heart failure. Cardiol Rev. 2009;17:56-9. This is a critical analysis of the existing literature on diuretics in heart failure.
66. Mielniczuk LM, TsangSW, Desai AS, Nohria A, Lewis EF, Fang JC, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14:388-93. This study introduces the concept that high dose of diuretics is a marker but not the cause of instability in heart failure. (Pubitemid 351749839)
67. Guglin M. Diuretics as pathogenetic treatment for heart failure. Int J Gen Med. 2011;4:91-8.
68. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265-72. This is a subanalysis of the ESCAPE trial showing mortality benefits from aggressive diuresis.
69. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.
70. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442-51.
71. Rubboli A, Sobotka PA, Euler DE. Effect of acute edema on left ventricular function and coronary vascular resistance in the isolated rat heart. Am J Physiol. 1994;267:H1054-61. (Pubitemid 24299055)
72. Parrinello G, Paterna S, Di Pasquale P, Torres D, Mezzero M, Cardillo M, et al. Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated heart failure. J Card Fail. 2011;17:331-9.
73. Ip JE, Cheung JW, Park D, Hellawell JL, Stein KM, Iwai S, et al. Temporal associations between thoracic volume overload and malignant ventricular arrhythmias: a study of intrathoracic impedance. J Cardiovasc Electrophysiol. 2011;22:293-9.
74. Moore HJ, Peters MN, Franz MR, Karasik PE, Singh SN, Fletcher RD. Intrathoracic impedance preceding ventricular tachyarrhythmia episodes. Pacing Clin Electrophysiol. 2010;33:960-6.